These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11401995)

  • 61. X-ray Irradiated Vaccine Confers protection against Pneumonia caused by Pseudomonas aeruginosa.
    Li Y; Wang Z; Liu X; Tang J; Peng B; Wei Y
    Sci Rep; 2016 Feb; 6():18823. PubMed ID: 26879055
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
    Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification.
    Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A
    Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
    Daoulas-Le Bourdelles F; Berche P; Véron M
    Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective activity of immune sera against extracellular slime from Pseudomonas aeruginosa on experimental infection in mice.
    Sokalska M; Maresz-Babczyszyn J
    Arch Immunol Ther Exp (Warsz); 1981; 29(5):643-52. PubMed ID: 6812542
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
    Sourek J; Výmola F; Zelenková L
    Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pseudomonas aeruginosa. Vaccines and immunotherapy.
    Pennington JE
    Infect Dis Clin North Am; 1990 Jun; 4(2):259-70. PubMed ID: 2111838
    [TBL] [Abstract][Full Text] [Related]  

  • 69. T cells recognizing polysaccharide-specific B cells function as contrasuppressor cells in the generation of T cell immunity to Pseudomonas aeruginosa.
    Powderly WG; Schreiber JR; Pier GB; Markham RB
    J Immunol; 1988 Apr; 140(8):2746-52. PubMed ID: 3128607
    [TBL] [Abstract][Full Text] [Related]  

  • 70. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Resistance to Pseudomonas aeruginosa septicemia in mice after transfer of immune spleen cells.
    Marlsz-Babczyszyn J; Sokalska M
    Arch Immunol Ther Exp (Warsz); 1983; 31(2):199-207. PubMed ID: 6606412
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of human gamma-globulin preparation in experimental pseudomonas aeruginosa infections in mice and its mode of action.
    Kamimura T
    Arzneimittelforschung; 1984; 34(11):1528-34. PubMed ID: 6084512
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A role for CD4+ T cells from orally immunized rats in enhanced clearance of Pseudomonas aeruginosa from the lung.
    Dunkley ML; Clancy RL; Cripps AW
    Immunology; 1994 Nov; 83(3):362-9. PubMed ID: 7835960
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effector mechanisms of protection against Pseudomonas aeruginosa keratitis in immunized rats.
    Thakur A; Kyd J; Xue M; Willcox MD; Cripps A
    Infect Immun; 2001 May; 69(5):3295-304. PubMed ID: 11292752
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.
    Krause A; Whu WZ; Xu Y; Joh J; Crystal RG; Worgall S
    Vaccine; 2011 Mar; 29(11):2131-9. PubMed ID: 21215829
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S; Kamboj K; Copfer J; Pier G; Green LL; Schreiber JR
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vaccines against Pseudomonas aeruginosa results and perspectives of investigations (survey).
    Joó I; Stanislavskii ES
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):417-27. PubMed ID: 6819316
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Immunization with the ferric iron-binding periplasmic protein HitA provides protection against Pseudomonas aeruginosa in the murine infection model.
    Elhosary MA; Bahey-El-Din M; AbdelBary A; El Guink N; Aboushleib HM
    Microb Pathog; 2019 Jun; 131():181-185. PubMed ID: 30978430
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Enhancement of the humoral immune response and resistance to bacterial infection in mice by the oral administration of a bacterial immunomodulator (OM-89).
    Bosch A; Benedi VJ; Pares R; Jofre J
    Immunopharmacol Immunotoxicol; 1988; 10(3):333-43. PubMed ID: 3143754
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Induction of protective immune responses against R5 human immunodeficiency virus type 1 (HIV-1) infection in hu-PBL-SCID mice by intrasplenic immunization with HIV-1-pulsed dendritic cells: possible involvement of a novel factor of human CD4(+) T-cell origin.
    Yoshida A; Tanaka R; Murakami T; Takahashi Y; Koyanagi Y; Nakamura M; Ito M; Yamamoto N; Tanaka Y
    J Virol; 2003 Aug; 77(16):8719-28. PubMed ID: 12885891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.